What is the appropriate management for an 83-year-old patient on hemodialysis with Stenotrophomonas maltophilia infection, Candida infection, liver dysfunction, coagulopathy, and secondary hyperparathyroidism?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 27, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of Multiple Infections in an 83-Year-Old Hemodialysis Patient

For this elderly hemodialysis patient with Stenotrophomonas maltophilia in sputum, Candida in urine, liver dysfunction, coagulopathy, and elevated parathyroid hormone, trimethoprim-sulfamethoxazole should be initiated for the S. maltophilia infection, and fluconazole 200mg daily (adjusted for renal function) for the Candida infection, with careful monitoring of liver function and INR.

Stenotrophomonas maltophilia Management

  • Trimethoprim-sulfamethoxazole (TMP-SMX) is the first-line treatment for S. maltophilia infections due to its good in vitro activity and favorable clinical outcomes 1
  • For patients on hemodialysis, TMP-SMX dosing should be adjusted for renal function, typically administered after dialysis sessions 2
  • Alternative options if TMP-SMX is contraindicated (given the patient's elevated liver enzymes and INR):
    • Minocycline has shown similar efficacy to TMP-SMX with potentially better tolerability in patients with renal dysfunction 3
    • Fluoroquinolones (e.g., levofloxacin) may be considered as part of combination therapy 1

Candida Infection Management

  • For Candida urinary tract infection in a hemodialysis patient, fluconazole is the recommended treatment 4
  • Initial dosing: 200mg daily, with subsequent doses adjusted for hemodialysis 5
  • For hemodialysis patients, fluconazole can be administered after dialysis sessions 4
  • Treatment duration should be 14 days after clinical improvement 4
  • Echinocandins (caspofungin, micafungin, or anidulafungin) are alternatives if fluconazole cannot be used due to liver dysfunction 4

Special Considerations for Hemodialysis Patients

  • Hemodialysis patients have unique challenges when managing infections 4:

    • Limited vascular access
    • Need for medication administration during dialysis sessions
    • Altered pharmacokinetics requiring dose adjustments
    • Higher risk of drug toxicity
  • Antibiotic dosing should be coordinated with dialysis schedule to ensure adequate drug levels 4

Addressing Liver Dysfunction and Coagulopathy

  • The elevated INR (2.9) and liver enzymes indicate significant liver dysfunction that requires careful medication selection 4
  • Monitor liver function tests and INR closely during antimicrobial therapy 4
  • Consider reducing doses of hepatically metabolized medications 4
  • Avoid medications with significant hepatotoxic potential when possible 4
  • The coagulopathy (INR 2.9) requires careful monitoring, especially if invasive procedures are needed 4

Management of Secondary Hyperparathyroidism

  • The elevated parathyroid hormone level (88.4) indicates secondary hyperparathyroidism, common in hemodialysis patients 4
  • This condition should be addressed but is not the immediate priority given the active infections
  • Standard management includes phosphate binders, vitamin D analogs, and calcimimetics 4

Monitoring and Follow-up

  • Obtain follow-up cultures to ensure clearance of infections 4
  • Monitor liver function tests, INR, and renal parameters regularly 4
  • Assess for drug interactions between antimicrobials and the patient's regular medications 4
  • Consider removal or exchange of any indwelling catheters if they are potential sources of infection 4
  • Evaluate for potential sources of infection to prevent recurrence 4

Potential Pitfalls and Caveats

  • S. maltophilia has intrinsic resistance to many antibiotics, making treatment challenging 1, 6
  • Hemodialysis patients are at higher risk for drug toxicity and altered pharmacokinetics 4
  • The combination of liver dysfunction and renal failure significantly limits medication options and requires careful dose adjustments 4
  • Elderly patients (83 years old) may have altered drug metabolism and increased susceptibility to adverse effects 4
  • Avoid nephrotoxic agents that could further damage residual kidney function 4

References

Research

Treatment approaches for severe Stenotrophomonas maltophilia infections.

Current opinion in infectious diseases, 2023

Research

Stenotrophomonas maltophilia peritonitis in a patient receiving automated peritoneal dialysis.

Advances in peritoneal dialysis. Conference on Peritoneal Dialysis, 2005

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Stenotrophomonas maltophilia infections.

Seminars in respiratory and critical care medicine, 2003

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.